Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
about
Fingolimod for relapsing-remitting multiple sclerosisFingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidenceFingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerationsClinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosisThe Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple SclerosisUse of natalizumab in multiple sclerosis: current perspectives.Efficacy and Safety of Fingolimod in Daily Practice: Experience of an Academic MS French CenterHigh-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study.Natalizumab in Multiple Sclerosis: Long-Term Management.The use of natalizumab for multiple sclerosisSafety of monoclonal antibodies for the treatment of multiple sclerosis.Use of Fingolimod in the Management of Relapsing-Remitting Multiple Sclerosis: Experience from Latin AmericaDesign of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center.Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers.Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosisα4-integrin receptor desaturation and disease activity return after natalizumab cessationFingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis.Disease activity return after natalizumab cessation in multiple sclerosis.Infectious Complications of Novel Multiple Sclerosis Therapies.Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar.Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis.Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis.The role of natalizumab in the treatment of multiple sclerosis: benefits and risks.Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients.Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors.Pulsed corticosteroid treatment in MS patients stabilizes disease activity following natalizumab withdrawal prior to switching to fingolimod.Reducing costs while enhancing quality of care in MS.The importance of collecting structured clinical information on multiple sclerosis.Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation.Bringing the HEET: The Argument for High-Efficacy Early Treatment for Pediatric-Onset Multiple Sclerosis.Disease reactivation after switching from natalizumab to daclizumab.Switching patients at high risk of PML from natalizumab to another disease-modifying therapy.Observational Study of Switching from Natalizumab to Immunomodulatory Drugs.Sometimes less is more in multiple sclerosis drug switching.Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal.[Current aspects of therapy conversion for multiple sclerosis].Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod
P2860
Q24185882-BE871C84-6547-4EEF-B47A-32D0FA47FA3DQ26752466-460E3DB8-73BA-461E-9A52-BF492238068DQ26765300-EE960860-5DCB-4FC4-8DE8-A93861FFB4B9Q26771635-8DAC9755-8B31-48D2-9D35-A05A1509F5D3Q28073377-14ABA7FA-1145-4C82-A48F-B19406B9F744Q31114633-13C927D3-6785-4B06-B057-C5A793AA1B81Q33639041-747FFFEE-EE13-4066-BE74-7A1F18A3F983Q33736193-F59226E6-DBBA-4CD4-8587-ECAB0E33F14BQ33754882-1835D84C-34F6-4EA1-8D4F-D58D993A053FQ33879159-D95A369A-E368-499B-9415-2C5B9F650584Q34542922-C4DB5E4E-413F-4807-BE50-C6E3CB35AFC9Q35907969-F2DEC70A-691E-4136-A4F6-9799F2B64D39Q36073992-3A8B864C-489A-4796-8BE2-65C3E212BA3CQ36379001-3AA23958-4282-4212-9F02-8624D5F0C439Q36389681-8F7FBC9A-FBCE-4BE0-BFD0-4A086764BB6DQ36484448-F822705E-E405-48A1-BE2A-178240D4864DQ38371432-A8BA5EE0-849F-48A8-8EA4-A9666F370318Q38606914-6A253C63-9BE2-4C16-8C80-2DE263AF37F8Q38779091-3C08EEBD-AA6B-47AD-B16F-3B357CD25DE0Q38944786-37950611-F2FE-4470-8D3F-5B6474D2CBB5Q39021942-E3D7675B-C078-4869-95D5-6964488B3F55Q39458666-72C086DB-CC62-4523-8AEF-493B3DB5A2E3Q40047199-C82D5F49-C87B-4D84-AD3A-0B73869047F7Q40061894-9870533A-8B58-434F-95DF-F96DDA4758E2Q40077487-4517B206-BEC2-48D2-BD33-17640572ED1CQ40747927-10576CF0-AD0F-4D6D-B3D8-23149CAC8696Q41002593-0C3ADAF5-11F3-417E-939A-E7CEA0FBBC95Q41966640-168A2CF8-9E6F-4012-A817-F3C67C1A7C88Q42747344-516BA74D-2097-4C5E-A9D2-78C171CC2D46Q48260043-ACF8E616-8F70-4CF1-9534-5BE0E1CBA274Q48664001-537FCD3F-E77B-426B-84A2-4501F5096F3FQ49631175-00037C53-E79E-49B4-B790-22BCC03E363AQ50858454-A525FD78-F6E9-44FB-83C9-2AB4F442F831Q51218322-2FD5DC18-61B9-4DCB-BFB5-B6DCADFCA5B4Q51553240-C0F77ACE-2CAD-4DC7-A070-406533C41F37Q52142630-7D4EECF7-58FF-4599-9701-F4F76F5AFA7AQ53582374-1D1BEA28-AF0A-4ABB-A86E-754B62E20A30Q58793277-C06FF5B2-99D4-432A-9301-F9EF1D35A84A
P2860
Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
@ast
Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
@en
type
label
Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
@ast
Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
@en
prefLabel
Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
@ast
Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
@en
P2093
P2860
P50
P1433
P1476
Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
@en
P2093
Davorka Tomic
Ernst-Wilhelm Radue
Frank Dahlke
Nicole Mueller-Lenke
Philipp von Rosenstiel
Rebecca Gottschalk
Sarah Griffiths
TOFINGO study group
Tobias Derfuss
Xavier Montalban
P2860
P356
10.1212/WNL.0000000000001706
P407
P50
P577
2015-05-29T00:00:00Z